Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Amit Sanyal, MD: A Clinician’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Aug

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Amit Sanyal, MD: A Clinician’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment

Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events

Charles WM Roberts Named President and Chief Executive Officer of St. Jude Children’s Research Hospital

Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?

Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer